Search
Repligen Corp
RGENAdd to Watchlist
131.940USD
-1.610-1.21%
Close 06/18, 16:00（ET）Quotes delayed by 15 min
7.43BMarket Cap
144.44P/E TTM
Earnings Forecast
Currency: USD Updated: 2026-06-17The current earnings forecast score of Repligen Corp is 8.09, ranking 65 out of 204 in the Healthcare Equipment & Supplies industry. The average price target is 190.00, with a high of 220.00 and a low of 160.00.
Analyst Rating
Based on
22
analysts
Buy
Current Rating
179.328
Target Price
+37.03%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
117
Total
6
Median
9
Average
Company name
Ratings
Analysts
Repligen Corp
RGEN
22
Medtronic PLC
MDT
33
Dexcom Inc
DXCM
32
Stryker Corp
SYK
32
Zimmer Biomet Holdings Inc
ZBH
31
Abbott Laboratories
ABT
30
1
2
3
...
24
Support & Resistance
Relevant data have not been disclosed by the company yet.
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
FAQs
What is Repligen Corp's expected revenue for the next quarter?
Repligen Corp's expected revenue is 201.51M.
What is Repligen Corp's price target?
Analysts forecast that Repligen Corp's price target is USD 190.00, with the highest forecast at USD 220.00 and the lowest forecast at USD 160.00.
How have Repligen CorpRGEN's recent earnings per share performed?
The market expectation was USD 0.15, while Repligen CorpRGEN's earnings per share (EPS) for the previous quarter was USD 0.24. EPS for the next quarter is expected at USD 0.45.
What is the analyst rating for Repligen Corp?
Based on the ratings of Repligen Corp's stock from 22 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.
